Clicky

CSL LTD SPON.ADR 2(CSJA)

Description: CSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and vaccines in Australia, the United States, Germany, the United Kingdom, Switzerland, China, Hong Kong, and internationally. The company operates through CSL Behring, CSL Seqirus, and CSL Vifor segments. The CSL Behring segment offers plasma products, gene therapies, and recombinants. The CSL Seqirus segment provides influenza related products and pandemic services to governments. The CSL Vifor segment offers products in the therapeutic areas of iron deficiency and nephrology. The company also licenses CSL intellectual property. CSL Limited was founded in 1916 and is headquartered in Melbourne, Australia.


Keywords: Influenza Pacific Century Group Iron Deficiency Csl Limited Plasma Products Csl Behring Behring Csl Csl Vifor Influenza Related Products Pandemic Services Vifor

Home Page: www.csl.com.au

655 Elizabeth Street
Melbourne, VIC 3000
Australia
Phone: 61 3 9389 1911


Officers

Name Title
Dr. Paul F. McKenzie Ph.D. MD, CEO & Executive Director
Ms. Joy Carolyn Linton B.Com., BComm, GAICD, Grad Dip AFI Interim Executive Vice President of CSL Behring
Mr. Andy Schmeltz Executive Vice President of CSL Behring Business Unit (Leave of Absence)
Mr. John A. G. Levy CPA Interim Chief Financial Officer
Chris Cooper Head of Investor Relations
Mr. Gregory Boss B.S., BS(Hons), J.D. Executive VP of Legal & General Counsel
Ms. Roanne Parry Chief Human Resources Officer
Dr. Andrew D. Nash BSc (Hons), GAICD, Ph.D. Senior Vice President of Research
Dr. William Mezzanotte M.D., M.P.H. Executive VP & Head of Research and Development
Mr. Mark Hill B.A., M.B.A. Chief Digital Information Officer & Executive VP

Exchange: F

Country: DE : Germany

Currency: Euro (€)

Forward PE: 32.4675
Trailing PE: 32.6848
Price-to-Book MRQ: 4.9593
Price-to-Sales TTM: 5.638
IPO Date:
Fiscal Year End: June
Full Time Employees: 32698
Back to stocks